Drug-eluting stents: a systematic review and economic evaluation

Abstract

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as r...

Comparison of the Effects of Bare Metal Stents and Drug Eluting Stents on C- Reactive Protein Levels

“…Periprocedural MI in our trial was 10% and it was consistent with the data of other trials with 7-10% periprocedural MI [7,21] . Adverse cardiac events frequency was not different between BMS and DES groups, similar to the published data [25] . Researchers investigated the relationship between adverse cardiac events and inflammation and myonecrosis levels postprocedurely [26,27] .…”

Clinical and Economic Outcomes of Liberal Versus Selective Drug-Eluting Stent Use

“…Recently, several health technology assessments have concluded that DES should be reserved for select patient subsets such as patients with diabetes mellitus or those with long lesions or small vessels. 10,11 However, these findings were based largely on a combination of expert opinion and decision-analytic models without external validation. 12,13 In January 2007, the US Food and Drug Administration responded to emerging safety concerns regarding DES with an advisory statement that cautioned against their use in patients with unapproved or untested indications.…”

Effectiveness and Efficiency of Drug Eluting Stents

“…In short, in relation to the use of DES, it is widely www.intechopen.com Coronary Artery Disease -Current Concepts in Epidemiology, Pathophysiology, Diagnostics and Treatment 206 acknowledged that its cost is the true limiting factor; for example, in our area the price of DES is 60-80% higher than conventional stents. Although many studies concluded that DES may be cost effective in large subgroups of patients, under real conditions, the DES costeffectiveness do not come out favorably compared to BMS (Neyt M et al 2009;Hill RA et al 2007;Kuukasjärvi P et al, 2007). …”